clinical trial · NCT06679270

Open-label Extension Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy

Amryt Pharma·phase3·recruiting·n = 24

Familial Partial LipodystrophyMetreleptin

brief summary

This Phase 3 study is an Open Label Extension of the APG-20 Study To Evaluate the Long-term Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects with Partial Lipodystrophy

started

Oct 14, 2024

primary completion

Mar 1, 2028

completion

Dec 1, 2028

last updated

Feb 2, 2026

official title

An Open-label Extension of APG-20 Study to Evaluate the Long-term Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With Partial Lipodystrophy

full record on clinicaltrials.gov ↗

sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol